应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
ABBV 艾伯维公司
休市中 12-20 15:59:59 EST
175.62
+4.10
+2.39%
盘后
175.00
-0.58
-0.33%
19:58 EST
最高
176.80
最低
170.66
成交量
1,895万
今开
171.79
昨收
171.52
日振幅
3.58%
总市值
3,103亿
流通市值
3,098亿
总股本
17.67亿
成交额
33.20亿
换手率
1.07%
流通股本
17.64亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
艾伯维上涨1.34%，报173.81美元/股
金融界 · 12-20 22:37
艾伯维上涨1.34%，报173.81美元/股
艾伯维下跌1.28%，报170.8美元/股
金融界网站 · 12-19 22:53
艾伯维下跌1.28%，报170.8美元/股
艾伯维下跌1.23%，报173.22美元/股
金融界 · 12-19
艾伯维下跌1.23%，报173.22美元/股
医药行业周报：艾伯维将以2亿美元收购NIMBLE 布局自免领域
太平洋证券股份... · 12-17
医药行业周报：艾伯维将以2亿美元收购NIMBLE 布局自免领域
艾伯维(ABBV.US)达成收购协议 布局自身免疫疾病领域
智通财经 · 12-16
艾伯维(ABBV.US)达成收购协议 布局自身免疫疾病领域
艾伯维下跌1.22%，报172.25美元/股
金融界 · 12-13
艾伯维下跌1.22%，报172.25美元/股
“股息贵族”引领2025？华尔街分析师看好这7只分红明星股
老虎资讯综合 · 12-12
“股息贵族”引领2025？华尔街分析师看好这7只分红明星股
艾伯维(ABBV.US)JAK抑制剂“乌帕替尼”在中国拟纳入优先审评
智通财经 · 12-11
艾伯维(ABBV.US)JAK抑制剂“乌帕替尼”在中国拟纳入优先审评
健康巡回：新型联合疗法有望治疗血癌
路透中文 · 12-11
健康巡回：新型联合疗法有望治疗血癌
艾伯维(ABBV.US)在研小分子疗法tavapadon达关键3期试验主要终点 预计于2025年递交上市申请
智通财经网 · 12-10
艾伯维(ABBV.US)在研小分子疗法tavapadon达关键3期试验主要终点 预计于2025年递交上市申请
艾伯维的帕金森病药物在后期研究中达到主要目标
Reuters · 12-09
艾伯维的帕金森病药物在后期研究中达到主要目标
【券商聚焦】花旗：艾伯维(ABBV)与施贵宝(BMY)增长潜力显著 行业聚焦商业化与新药管线
金吾财讯 · 12-06
【券商聚焦】花旗：艾伯维(ABBV)与施贵宝(BMY)增长潜力显著 行业聚焦商业化与新药管线
艾伯维下跌3.03%，报176.0美元/股
金融界 · 12-05
艾伯维下跌3.03%，报176.0美元/股
独家-消息人士称，大型对冲基金向医生和科学家求助，以求在制药业获得优势
路透中文 · 12-04
独家-消息人士称，大型对冲基金向医生和科学家求助，以求在制药业获得优势
焦点-大型制药公司推动特朗普团队放宽医疗保险药品价格谈判规则
路透中文 · 11-28
焦点-大型制药公司推动特朗普团队放宽医疗保险药品价格谈判规则
华东医药：索米妥昔单抗注射液上市许可申请获得批准
智通财经网 · 11-27
华东医药：索米妥昔单抗注射液上市许可申请获得批准
健康巡讲广泛使用的甲状腺药片可能与骨质流失有关
路透中文 · 11-27
健康巡讲广泛使用的甲状腺药片可能与骨质流失有关
健康巡讲广泛使用的甲状腺药片可能与骨质流失有关
路透中文 · 11-27
健康巡讲广泛使用的甲状腺药片可能与骨质流失有关
艾伯维上涨1.22%，报179.22美元/股
金融界 · 11-27
艾伯维上涨1.22%，报179.22美元/股
艾伯维上涨1.23%，报179.13美元/股
金融界 · 11-25
艾伯维上涨1.23%，报179.13美元/股
加载更多
公司概况
公司名称：
艾伯维公司
所属市场：
NYSE
上市日期：
--
主营业务：
艾伯维公司注册成立于2012年4月10日，是一家全球性的、以研究为基础的生物制药公司。Abbvie公司从事开发和销售先进的疗法，来解决一些世界上最复杂和严重的疾病。Abbvie公司的产品主要集中在慢性自身免疫性疾病领域，包括类风湿性关节炎，牛皮癣和克罗恩病，银屑病和克罗恩病;低睾酮，HIV，子宫内膜异位症;甲状腺疾病;帕金森病;和并发症的慢性肾脏疾病和囊性纤维化相关的或其他健康问题。
发行价格：
--
{"stockData":{"symbol":"ABBV","market":"US","secType":"STK","nameCN":"艾伯维公司","latestPrice":175.62,"timestamp":1734728399937,"preClose":171.52,"halted":0,"volume":18950887,"hourTrading":{"tag":"盘后","latestPrice":175,"preClose":175.58,"latestTime":"19:58 EST","volume":6707208,"amount":1177651685.57465,"timestamp":1734742712401},"delay":0,"floatShares":1764026621,"shares":1767140323,"eps":2.869915,"marketStatus":"休市中","marketStatusCode":7,"change":4.1,"latestTime":"12-20 15:59:59 EST","open":171.794,"high":176.7999,"low":170.66,"amount":3319617021.32876,"amplitude":0.035797,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.869915,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1734944400000},"adr":0,"adjPreClose":171.52,"adrRate":0,"dividendRate":0.035303,"preHourTrading":{"tag":"盘前","latestPrice":172.01,"preClose":171.52,"latestTime":"09:29 EST","volume":441981,"amount":75808130.29938,"timestamp":1734704999752},"postHourTrading":{"tag":"盘后","latestPrice":175,"preClose":175.58,"latestTime":"19:58 EST","volume":6707208,"amount":1177651685.57465,"timestamp":1734742712401},"volumeRatio":2.8821347630670724,"impliedVol":0.2806,"impliedVolPercentile":0.8492},"requestUrl":"/m/hq/s/ABBV","defaultTab":"news","newsList":[{"id":"2492442629","title":"艾伯维上涨1.34%，报173.81美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492442629","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492442629?lang=zh_cn&edition=full","pubTime":"2024-12-20 22:37","pubTimestamp":1734705449,"startTime":"0","endTime":"0","summary":"12月20日，艾伯维(ABBV)盘中上涨1.34%，截至22:37，报173.81美元/股，成交2.86亿美元。财务数据显示，截至2024年09月30日，艾伯维收入总额412.32亿美元，同比增长3.04%；归母净利润43.0亿美元，同比增长6.41%。大事提醒：12月17日，艾伯维获Piper Sandler上调目标价至220美元，最新评级Overweight。2025年2月7日，艾伯维将披露2024财年年报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际披露日期以公司公告为准）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220224139a1fe2965&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220224139a1fe2965&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU0965509010.AUD","LU1093756325.SGD","ABBV","LU1244550577.SGD","LU2112291526.USD","LU2468319806.SGD","LU1023059063.AUD","LU0912757837.SGD","LU1057294990.SGD","LU1291159041.SGD","IE0004445239.USD","LU0553294199.USD","SG9999015945.SGD","LU1244550494.USD","BK4581","BK4534","LU1585245621.USD","LU1267930573.SGD","LU0861579265.USD","LU0965509283.SGD","LU0689472784.USD","IE0002141913.USD","LU1496350171.SGD","LU0122379950.USD","LU0708994859.HKD","LU0417517546.SGD","SG9999003800.SGD","IE00B42XCP33.USD","BK4588","IE00BVYPNV92.GBP","IE00BGHQF631.EUR","LU0738911758.USD","LU0256863902.USD","IE00BVYPNW00.USD","LU1989772840.SGD","LU1496350502.SGD","SG9999015978.USD","LU2133065610.SGD","LU2347655156.SGD","LU1732800096.USD","SG9999011175.SGD","IE00BSNM7G36.USD","LU2237443978.SGD","LU0256863811.USD","LU0114720955.EUR","IE00B4R5TH58.HKD","IE00BDGV0183.EUR","LU1093756168.USD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2492195172","title":"艾伯维下跌1.28%，报170.8美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492195172","media":"金融界网站","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492195172?lang=zh_cn&edition=full","pubTime":"2024-12-19 22:53","pubTimestamp":1734619980,"startTime":"0","endTime":"0","summary":"12月19日，艾伯维(ABBV)盘中下跌1.28%，截至22:53，报170.8美元/股，成交6343.12万美元。财务数据显示，截至2024年09月30日，艾伯维收入总额412.32亿美元，同比增长3.04%；归母净利润43.0亿美元，同比增长6.41%。大事提醒：12月17日，艾伯维获Piper Sandler上调目标价至220美元，最新评级Overweight。2025年2月7日，艾伯维将披露2024财年年报。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/us/2024-12-19/doc-inczzitm9815680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0820561909.HKD","LU0128525929.USD","LU0234572021.USD","IE00B3PB1722.GBP","LU1244550577.SGD","LU1989771016.USD","ABBV","LU1093756168.USD","LU0114720955.EUR","LU2112291526.USD","LU0310800379.SGD","LU2133065610.SGD","LU1244550494.USD","LU0708994859.HKD","LU0158827948.USD","LU0965509101.SGD","LU2089984988.USD","LU1934455277.USD","IE00BJT1NW94.SGD","SG9999015986.USD","LU1496350171.SGD","IE00B2B36J28.USD","LU1732799900.SGD","BK4550","LU2087621335.USD","IE00BVYPNW00.USD","LU0965508806.USD","LU1244550221.USD","LU0203345920.USD","IE00BVYPNV92.GBP","LU0256863902.USD","LU0545039389.USD","LU1023059063.AUD","LU0795875086.SGD","BK4588","IE00BSNM7G36.USD","LU0965509010.AUD","LU0795875169.SGD","LU1291159041.SGD","LU0170899867.USD","LU0949170772.SGD","LU2023251221.USD","SG9999011175.SGD","BK4534","LU1057294990.SGD","LU1934455863.HKD","LU2237443549.SGD","IE0004445239.USD","BK4139","BK4566"],"gpt_icon":0},{"id":"2492154222","title":"艾伯维下跌1.23%，报173.22美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492154222","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492154222?lang=zh_cn&edition=full","pubTime":"2024-12-19 04:57","pubTimestamp":1734555446,"startTime":"0","endTime":"0","summary":"12月19日，艾伯维(ABBV)盘中下跌1.23%，截至04:57，报173.22美元/股，成交6.56亿美元。财务数据显示，截至2024年09月30日，艾伯维收入总额412.32亿美元，同比增长3.04%；归母净利润43.0亿美元，同比增长6.41%。大事提醒：12月17日，艾伯维获Piper Sandler上调目标价至220美元，最新评级Overweight。2025年2月7日，艾伯维将披露2024财年年报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际披露日期以公司公告为准）。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/19045746566344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU0949170772.SGD","LU2237443382.USD","LU1093756325.SGD","IE00BJJMRZ35.SGD","BK4559","IE00BFTCPJ56.SGD","LU0943347566.SGD","LU2023251221.USD","LU1989772840.SGD","IE00BDGV0183.EUR","LU1551013425.SGD","LU0545039389.USD","LU1244550577.SGD","LU0211328371.USD","LU0029864427.USD","IE0004445239.USD","LU1732800096.USD","LU1430594728.SGD","BK4534","SG9999015952.SGD","LU0203347892.USD","LU0861579265.USD","LU2089283258.USD","BK4585","IE0002141913.USD","IE00B2B36J28.USD","LU0965509283.SGD","LU1267930490.SGD","LU0985320562.USD","LU0795875086.SGD","LU2237443465.HKD","LU1057294990.SGD","LU0310799852.SGD","LU2112291526.USD","ABBV","LU0689472784.USD","SG9999015978.USD","LU1093756168.USD","LU1244550494.USD","IE00BGHQF631.EUR","LU1934455194.USD","LU2468319806.SGD","LU1718418525.SGD","LU0661504455.SGD","LU1496350502.SGD","BK4139","LU2237443549.SGD","LU0553294199.USD","LU0198837287.USD","LU1061106388.HKD"],"gpt_icon":0},{"id":"2492588601","title":"医药行业周报：艾伯维将以2亿美元收购NIMBLE 布局自免领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2492588601","media":"太平洋证券股份...","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492588601?lang=zh_cn&edition=full","pubTime":"2024-12-17 00:00","pubTimestamp":1734364800,"startTime":"0","endTime":"0","summary":"行业要闻：近日，艾伯维宣布，将以2 亿美元现金收购Nimble，并提供一定的中期资金支持和里程碑付款，从而获得其核心资产口服肽类IL-23 受体IL-23R 抑制剂，以及覆盖多种自身免疫疾病的创新口服肽候选药物管线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217120201ab7e131c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217120201ab7e131c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0002141913.USD","LU0965509283.SGD","LU0965509010.AUD","LU0310799852.SGD","SG9999003800.SGD","LU0708994859.HKD","LU1267930490.SGD","IE0009355771.USD","LU0661504455.SGD","LU1003077747.HKD","LU0256863902.USD","LU1057294990.SGD","BK4559","LU2347655156.SGD","LU0122379950.USD","BK4533","LU1989772923.USD","SG9999011175.SGD","BK4585","LU0689472784.USD","LU0949170772.SGD","LU1732799900.SGD","LU1732800096.USD","IE00BDGV0183.EUR","IBD","IE00B42XCP33.USD","LU0795875169.SGD","LU0256863811.USD","LU1934455277.USD","LU1496350171.SGD","BK4550","LU0820561818.USD","ABBV","LU0128525929.USD","BK4566","LU0417517546.SGD","LU0965508806.USD","LU0310800379.SGD","LU0861579265.USD","LU2237443622.USD","LU0211328371.USD","LU1244550221.USD","BK4139","LU0985320562.USD","IE00BFTCPJ56.SGD","LU1291159041.SGD","IE00BGHQF631.EUR","LU2237443895.HKD","LU2023251221.USD","LU0553294199.USD"],"gpt_icon":0},{"id":"2491695631","title":"艾伯维(ABBV.US)达成收购协议 布局自身免疫疾病领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2491695631","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491695631?lang=zh_cn&edition=full","pubTime":"2024-12-16 21:07","pubTimestamp":1734354475,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，艾伯维与Nimble Therapeutics宣布达成最终协议，艾伯维将收购Nimble，并获得其核心资产，包括主打项目——口服肽类IL-23受体抑制剂，以及覆盖多种自身免疫疾病的创新口服肽候选药物管线。根据协议条款，艾伯维将在交易完成时支付2亿美元现金用于收购Nimble，同时提供一定的中期资金支持。此外，Nimble的股东在达成特定开发里程碑后，还将有机会获得额外的潜在付款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225651.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"艾伯维(ABBV.US)达成收购协议 布局自身免疫疾病领域","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0128525929.USD","LU0882574055.USD","LU1718418525.SGD","LU0211327993.USD","LU1732799900.SGD","LU1244550494.USD","LU2468319806.SGD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU1983299246.USD","LU2087621335.USD","IE00BVYPNV92.GBP","IE00BDGV0183.EUR","BK4550","LU0417517546.SGD","LU1989772923.USD","LU2023251221.USD","IE00B42XCP33.USD","LU0795875169.SGD","LU0965509283.SGD","LU1093756168.USD","LU0234570918.USD","IE0004445239.USD","LU0029864427.USD","BK4566","LU0158827948.USD","LU0912757837.SGD","LU1023059063.AUD","LU0310800379.SGD","SG9999003800.SGD","LU1551013425.SGD","SG9999015978.USD","LU0689472784.USD","LU0820561909.HKD","LU0114720955.EUR","LU0203347892.USD","LU1989771016.USD","LU2089984988.USD","LU1496350502.SGD","SG9999015952.SGD","LU0170899867.USD","LU1093756325.SGD","LU1839511570.USD","LU0795875086.SGD","LU0122379950.USD","IE00BSNM7G36.USD","ABBV","BK4581","LU1244550221.USD","LU1934455863.HKD"],"gpt_icon":0},{"id":"2491355366","title":"艾伯维下跌1.22%，报172.25美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2491355366","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491355366?lang=zh_cn&edition=full","pubTime":"2024-12-13 02:59","pubTimestamp":1734029944,"startTime":"0","endTime":"0","summary":"12月13日，艾伯维(ABBV)盘中下跌1.22%，截至02:59，报172.25美元/股，成交3.26亿美元。财务数据显示，截至2024年09月30日，艾伯维收入总额412.32亿美元，同比增长3.04%；归母净利润43.0亿美元，同比增长6.41%。大事提醒：12月10日，艾伯维获美国银行重申评级Neutral，目标价上调至191美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/13025946339871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU0310800379.SGD","LU0553294199.USD","LU0198837287.USD","LU0203345920.USD","LU0114720955.EUR","LU2237443978.SGD","LU1732800096.USD","LU0820561818.USD","LU0128525929.USD","IE00BSNM7G36.USD","LU2237443382.USD","ABBV","LU0949170772.SGD","LU1430594728.SGD","LU2237443622.USD","LU0211327993.USD","LU1244550494.USD","LU0985320562.USD","LU0861579265.USD","LU1496350502.SGD","LU0310799852.SGD","LU0738911758.USD","LU1551013342.USD","SG9999001440.SGD","LU0965508806.USD","LU0912757837.SGD","SG9999003800.SGD","LU1496350171.SGD","LU0234572021.USD","LU0256863811.USD","LU2237443895.HKD","IE00BDGV0183.EUR","SG9999015986.USD","IE00BJJMRZ35.SGD","LU0456855351.SGD","LU0689472784.USD","SG9999015952.SGD","LU1037948541.HKD","SG9999015945.SGD","BK4139","LU1551013425.SGD","LU1244550221.USD","IE00BFTCPJ56.SGD","IE00BVYPNW00.USD","LU2347655156.SGD","LU1061106388.HKD","LU0170899867.USD","LU2133065610.SGD","LU0234570918.USD","LU0820561909.HKD"],"gpt_icon":0},{"id":"1164648197","title":"“股息贵族”引领2025？华尔街分析师看好这7只分红明星股","url":"https://stock-news.laohu8.com/highlight/detail?id=1164648197","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164648197?lang=zh_cn&edition=full","pubTime":"2024-12-12 15:26","pubTimestamp":1733988379,"startTime":"0","endTime":"0","summary":"随着投资者对美股股票的乐观情绪继续在2025年高涨，分析师们关注了一些高股息股票，认为这是押注市场、降低风险并同时获得收益的一种方式。股息贵族指的是那些在过去25年里每年都提高股息的公司。该分析师还指出，艾伯维的新药和治疗方案管线尚未被充分认可。TD Cowen将其目标价设定为每股225美元，这表明艾伯维的股票还有约27%的上涨潜力。2024年，其股价上涨约6%，目前的股息收益率为4.2%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/097a4bdb683a734d2e3b53d5cc32e699","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/097a4bdb683a734d2e3b53d5cc32e699"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"4713b7396400ba3af77fa855708651ff","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"“股息贵族”引领2025？华尔街分析师看好这7只分红明星股","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABT","APD","KO","CVX","BDX","ABBV","NEE","NOBL"],"gpt_icon":1},{"id":"2490070499","title":"艾伯维(ABBV.US)JAK抑制剂“乌帕替尼”在中国拟纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2490070499","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490070499?lang=zh_cn&edition=full","pubTime":"2024-12-11 10:03","pubTimestamp":1733882580,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，12月10日，中国国家药监局药品审评中心官网公示，艾伯维申报的乌帕替尼缓释片拟纳入优先审评，拟定适应症为治疗成人巨细胞动脉炎。乌帕替尼缓释片是一种JAK抑制剂，此前已在中国获批治疗多种其它适应症。GCA通常影响50岁以上的老年患者，最常见的年龄段在70至80岁之间。根据研究结果，乌帕替尼缓释片有可能成为GCA患者的第一个口服治疗药物选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"艾伯维(ABBV.US)JAK抑制剂“乌帕替尼”在中国拟纳入优先审评","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1934455194.USD","LU1037948897.HKD","LU2133065610.SGD","LU0256863811.USD","LU0158827948.USD","LU1244550494.USD","LU1732800096.USD","LU1057294990.SGD","LU0128525929.USD","LU0820561818.USD","LU1267930573.SGD","LU0661504455.SGD","LU0820561909.HKD","LU1430594728.SGD","LU0256863902.USD","IE00BSNM7G36.USD","LU0417517546.SGD","BK4566","LU2087621335.USD","LU1551013425.SGD","LU0795875086.SGD","LU0198837287.USD","LU1037948541.HKD","IE00B42XCP33.USD","LU1003077747.HKD","SG9999015978.USD","SG9999003800.SGD","BK4534","IE00BVYPNW00.USD","SG9999015986.USD","LU1983299246.USD","SG9999011175.SGD","LU0985320562.USD","LU1291159041.SGD","ABBV","SG9999015945.SGD","LU0912757837.SGD","LU1093756168.USD","LU0234572021.USD","SG9999001440.SGD","LU2089984988.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU2237443622.USD","BK4585","LU0949170772.SGD","IE0002141913.USD","IE00B4R5TH58.HKD","LU1718418525.SGD","LU0882574055.USD"],"gpt_icon":0},{"id":"2490023042","title":"健康巡回：新型联合疗法有望治疗血癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2490023042","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490023042?lang=zh_cn&edition=full","pubTime":"2024-12-11 04:36","pubTimestamp":1733863013,"startTime":"0","endTime":"0","summary":"三联药物疗法有望治疗血癌 研究人员在美国血液学学会 会议上报告说，新型三联药物疗法有望治疗各种白血病患者。该疗法的总体反应率为 82%。\"我们看到的结果确实将这种三联疗法定位为一种潜在的标准治疗方案。\"如今，我们有几位患者已经不再接受治疗，而是通过定期的血液MRD检测进行监测。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nL4S3NB1LV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU0820561818.USD","LU0965509101.SGD","LU0738911758.USD","LU1003077747.HKD","LU2324357040.USD","LU0029864427.USD","LU1366192091.USD","LU0079474960.USD","LU0553294199.USD","LU1551013425.SGD","LU2133065610.SGD","LU2491050071.SGD","BK4139","ABBV","LU1074936037.SGD","SG9999015952.SGD","IE00BSNM7G36.USD","IE00B2B36J28.USD","LU0965509010.AUD","LU1035775433.USD","IE00BVYPNV92.GBP","LU2347655156.SGD","LU2242652126.USD","LU2461242641.AUD","IE00B4R5TH58.HKD","SG9999015978.USD","LU1261432733.SGD","LU0109391861.USD","SNDX","SG9999018865.SGD","IE00B3PB1722.GBP","LU2360032135.SGD","BMY","LU0310799852.SGD","LU1323610961.USD","LU1496350502.SGD","LU0225771236.USD","LU1023059063.AUD","BK4559","LU2237443382.USD","LU2237443622.USD","SG9999017495.SGD","LLY","LU2264538146.SGD","LU1732799900.SGD","SGXZ31699556.SGD","LU1712237335.SGD","LU2125154778.USD","LU0006306889.USD"],"gpt_icon":1},{"id":"2490980052","title":"艾伯维(ABBV.US)在研小分子疗法tavapadon达关键3期试验主要终点 预计于2025年递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2490980052","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490980052?lang=zh_cn&edition=full","pubTime":"2024-12-10 14:12","pubTimestamp":1733811122,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，艾伯维今日公布其关键性3期TEMPO-2试验的积极顶线结果。分析显示，其在研小分子疗法tavapadon作为灵活剂量单药治疗早期帕金森病患者时达成主要终点。此外，作为一种半衰期为24小时的部分激动剂，tavapadon可以每日服用一次，从而避免多巴胺受体的过度激活所造成的运动障碍。艾伯维在新闻稿中指出，tavapadon的有效性和安全耐受性使其能够在早期帕金森病患者中发挥作用，与艾伯维现有针对症状性的晚期帕金森病疗法管线成为互补。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["IE0002141913.USD","SG9999003800.SGD","LU1244550577.SGD","LU0256863902.USD","LU0029864427.USD","LU0122379950.USD","BK4533","LU1061106388.HKD","LU0820561909.HKD","LU0882574055.USD","LU0943347566.SGD","BK4585","LU1585245621.USD","LU1989772923.USD","SG9999011175.SGD","LU1093756325.SGD","LU1496350502.SGD","LU0949170772.SGD","LU1934455863.HKD","LU2237443465.HKD","SG9999001440.SGD","LU1732799900.SGD","LU0198837287.USD","SG9999015952.SGD","IE00BDGV0183.EUR","LU2089984988.USD","LU1037948541.HKD","LU0965509101.SGD","BK4550","LU2237443382.USD","LU1934455194.USD","LU0820561818.USD","LU2089283258.USD","IE00BVYPNW00.USD","ABBV","LU0417517546.SGD","LU2112291526.USD","LU0738911758.USD","LU0965508806.USD","LU0310800379.SGD","LU2237443622.USD","LU0211328371.USD","LU0456855351.SGD","IE00BFTCPJ56.SGD","SG9999015945.SGD","LU1291159041.SGD","LU1989771016.USD","LU1983299246.USD","IE00B2B36J28.USD","LU0553294199.USD"],"gpt_icon":0},{"id":"2490724973","title":"艾伯维的帕金森病药物在后期研究中达到主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2490724973","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490724973?lang=zh_cn&edition=full","pubTime":"2024-12-09 21:04","pubTimestamp":1733749445,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 )) 路透12月9日 - 艾伯维 周一表示，其治疗帕金森病的实验性药物在一项后期研究中达到了主要目标。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999003800.SGD","LU1003077747.HKD","LU0689472784.USD","LU1839511570.USD","BK4533","LU1093756325.SGD","BK4588","IE0004445239.USD","LU0128525929.USD","IE0009355771.USD","LU0820561909.HKD","LU2089283258.USD","LU0256863811.USD","LU1244550221.USD","LU0203347892.USD","LU1934455194.USD","SG9999015952.SGD","IE00B2B36J28.USD","ABBV","LU0234570918.USD","LU0708994859.HKD","LU1244550494.USD","LU1496350502.SGD","IE00BVYPNV92.GBP","LU2237443895.HKD","LU1037948897.HKD","BK4566","LU0553294199.USD","LU1718418525.SGD","IE00B3PB1722.GBP","LU0795875169.SGD","IE00BSNM7G36.USD","SG9999001440.SGD","LU1732800096.USD","LU0943347566.SGD","LU0234572021.USD","LU2237443978.SGD","LU0122379950.USD","LU1585245621.USD","SG9999015978.USD","LU2237443465.HKD","LU0114720955.EUR","SG9999015986.USD","LU0256863902.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU1093756168.USD","LU0198837287.USD","IE00BVYPNW00.USD","LU0965508806.USD"],"gpt_icon":0},{"id":"2489263134","title":"【券商聚焦】花旗：艾伯维(ABBV)与施贵宝(BMY)增长潜力显著 行业聚焦商业化与新药管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2489263134","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489263134?lang=zh_cn&edition=full","pubTime":"2024-12-06 10:53","pubTimestamp":1733453617,"startTime":"0","endTime":"0","summary":"会议重点讨论了艾伯维和施贵宝等公司的最新商业执行情况、临床催化剂以及近期推出的产品和标签扩展机会。关于艾伯维，花旗认为公司的重点将继续是Skyrizi和Rinvoq的商业化执行，以及其美容业务的反弹潜力和emraclidine的下一步计划。Skyrizi在溃疡性结肠炎中的增长与克罗恩病的增长相一致，显示出高效力和市场对生物制剂的高接受度。花旗对该公司维持“买入”评级，目标价215美元。对于百时美施贵宝，花旗认为公司的新药上市和管线是缓解收入低谷的关键。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/NjJlY2NjZTdjZjEwMTc4NjkxNjc4NQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjJlY2NjZTdjZjEwMTc4NjkxNjc4NQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"282857","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJLML261.HKD","LU2462157665.USD","LU0985481810.HKD","LU0198837287.USD","LU2417539215.USD","LU1267930490.SGD","LLY","LU0170899867.USD","SG9999013999.USD","LU0128525689.USD","LU0321505868.SGD","LU0417517546.SGD","LU2602419157.SGD","LU0738911758.USD","SG9999015978.USD","IE00BSNM7G36.USD","IE00BFTCPJ56.SGD","LU2324357040.USD","BK4599","BMY","LU0943347566.SGD","LU1366192091.USD","LU0949170772.SGD","LU1670710588.SGD","LU0029864427.USD","BIIB","LU0203202063.USD","LU0211327993.USD","LU0661504455.SGD","LU2265009873.SGD","BK4566","IE00B3PB1722.GBP","LU1571399168.USD","IE00BJT1NW94.SGD","LU1989771016.USD","BK4581","IE00B2B36J28.USD","LU0310800965.SGD","LU1003077747.HKD","LU0354030511.USD","ABBV","LU2491050154.USD","LU0385154629.USD","LU2264538146.SGD","LU2361045086.USD","IE00BDGV0183.EUR","LU0256863902.USD","LU1791807156.HKD","IE00B4R5TH58.HKD","LU1934455194.USD"],"gpt_icon":1},{"id":"2489429341","title":"艾伯维下跌3.03%，报176.0美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2489429341","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489429341?lang=zh_cn&edition=full","pubTime":"2024-12-05 04:31","pubTimestamp":1733344287,"startTime":"0","endTime":"0","summary":"12月5日，艾伯维(ABBV)盘中下跌3.03%，截至04:31，报176.0美元/股，成交6.31亿美元。财务数据显示，截至2024年09月30日，艾伯维收入总额412.32亿美元，同比增长3.04%；归母净利润43.0亿美元，同比增长6.41%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/05043146033043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4139","LU1037948897.HKD","LU2133065610.SGD","LU1732800096.USD","LU1839511570.USD","LU1057294990.SGD","LU0128525929.USD","LU0820561818.USD","LU0795875169.SGD","LU0820561909.HKD","SG9999015952.SGD","IE00BSNM7G36.USD","LU2237443465.HKD","LU0417517546.SGD","BK4581","LU1093756325.SGD","LU2087621335.USD","LU1551013425.SGD","LU1267930490.SGD","LU2089284900.SGD","IE00B42XCP33.USD","BK4559","SG9999015978.USD","LU1989771016.USD","SG9999003800.SGD","LU2023251221.USD","IE00BVYPNW00.USD","LU0456855351.SGD","LU0211328371.USD","LU0965509101.SGD","LU1585245621.USD","ABBV","LU2237443382.USD","SG9999015945.SGD","LU0912757837.SGD","LU0114720955.EUR","LU1093756168.USD","LU2237443895.HKD","LU2089283258.USD","LU1732799900.SGD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU0738911758.USD","IE0002141913.USD","LU0211327993.USD","LU1718418525.SGD","LU0882574055.USD","LU0203347892.USD","LU0310800379.SGD","LU0545039389.USD"],"gpt_icon":0},{"id":"2488713604","title":"独家-消息人士称，大型对冲基金向医生和科学家求助，以求在制药业获得优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2488713604","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488713604?lang=zh_cn&edition=full","pubTime":"2024-12-04 14:00","pubTimestamp":1733292024,"startTime":"0","endTime":"0","summary":"独家-消息人士称，大型对冲基金向医生和科学家求助，以求在制药业获得优势招聘医生的趋势从美国蔓延至欧洲--招聘公司借贷成本下降，医药研发支出有望增加欧洲企业今年财报日波动较大Nell Mackenzie. 路透社伦敦12月4日 - 八位消息人士告诉路透社，全球最大的一些对冲基金正在招聘医生、科学家和分析师，以便在医药行业股价大幅波动后对该行业的前景有专业的见解。专家们指出，多策略对冲基金是造成这种现象的原因之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nL3S3N50CM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0795875169.SGD","LU0985320562.USD","LU1323610961.USD","ABBV","LU0661504455.SGD","LU1732799900.SGD","LU2237443622.USD","LU1551013342.USD","LU2237443549.SGD","BMY","LU0203347892.USD","SG9999001440.SGD","LU2237443465.HKD","LU0820561909.HKD","LU1430594728.SGD","LU2125154778.USD","LU0203345920.USD","LU0321505868.SGD","LU1551013425.SGD","LU1267930490.SGD","LU1244550494.USD","LU1571399168.USD","LU1585245621.USD","LU2237443895.HKD","LU0861579265.USD","LU2087621335.USD","IE0002141913.USD","LU1868836914.USD","LU0158827948.USD","LU0708994859.HKD","LU0820561818.USD","LU1032466523.USD","LU0310800379.SGD","LU1261432733.SGD","LU1868837136.USD","IE00BGHQF631.EUR","LU1989772840.SGD","BK4585","LU0868494617.USD","SG9999015978.USD","LU1732800096.USD","LU1983299246.USD","LU2237443978.SGD","LU2089283258.USD","LU0795875086.SGD","LU0985481810.HKD","BK4566","LU2112291526.USD","BK4559","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2486709548","title":"焦点-大型制药公司推动特朗普团队放宽医疗保险药品价格谈判规则","url":"https://stock-news.laohu8.com/highlight/detail?id=2486709548","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486709548?lang=zh_cn&edition=full","pubTime":"2024-11-28 01:48","pubTimestamp":1732729737,"startTime":"0","endTime":"0","summary":"焦点-大型制药公司推动特朗普团队放宽医疗保险药品价格谈判规则制药业要求在大多数药物符合医疗保险价格谈判条件之前给予更多时间业界称目前的谈判条款将扼杀创新共和党人被视为修改《通货膨胀削减法》的盟友Michael Erman/Patrick Wingrove/Maggie Fick. 等待共和党 一家大型制药公司的一位消息人士称，该公司与特朗普过渡团队的成员进行了电话和面谈，讨论对《爱尔兰共和军法》可能进行的修改。特朗普过渡团队没有回应置评请求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241127:nL3T3MY18N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0757432116.USD","LU0784384876.USD","IE00B19Z3581.USD","IE00BBT3K403.USD","LU1051770623.HKD","LU0256863811.USD","IE00B3PB1722.GBP","LU1023059063.AUD","LU1732800096.USD","LU1883839398.USD","LU2347655156.SGD","LU0997586432.USD","LU2242646821.SGD","LU2112291526.USD","LU0310800965.SGD","AMGN","LU0345777147.USD","LU1066053197.SGD","SG9999014542.SGD","LU1670711123.USD","MRK","LU1989772923.USD","JNJ","BK4550","AZN.UK","LU1929549753.HKD","LU0795875086.SGD","03165","IE00B42XCP33.USD","LU0109394709.USD","BMY","LU0823416689.USD","LU1670710588.SGD","LU0320765646.SGD","SG9999003800.SGD","IE00BDGV0183.EUR","LU1267930227.SGD","LU1003076772.USD","SG9999011175.SGD","LU0234570918.USD","LU1487256676.USD","ABBV","LU1935042991.SGD","LU0912757837.SGD","LU1084165304.USD","LU0047473722.EUR","IE0009355771.USD","IE00BFTCPJ56.SGD","PFE","LU0310799852.SGD"],"gpt_icon":1},{"id":"2486841601","title":"华东医药：索米妥昔单抗注射液上市许可申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2486841601","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486841601?lang=zh_cn&edition=full","pubTime":"2024-11-27 18:17","pubTimestamp":1732702657,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华东医药 发布公告，2024年11月27日，公司全资子公司杭州中美华东制药有限公司收到国家药品监督管理局核准签发的《药品注册证书》，中美华东申报的索米妥昔单抗注射液用于既往接受过1-3线系统性治疗的叶酸受体α阳性的铂类耐药卵巢癌适应症的上市许可申请获得批准。2022年11月，ImmunoGen宣布该产品获得美国FDA加速批准上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127182229a2597819&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127182229a2597819&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0661504455.SGD","LU0114720955.EUR","LU0965508806.USD","LU0310800379.SGD","LU1037948541.HKD","LU0029864427.USD","LU1291159041.SGD","IE00BJT1NW94.SGD","LU1718418525.SGD","EC","LU1934455194.USD","PROC","BK4533","IE00B2B36J28.USD","LU1061106388.HKD","LU0861579265.USD","IE0004445239.USD","BK4585","ABBV","IE00B42XCP33.USD","LU1496350171.SGD","LU0965509010.AUD","LU1023059063.AUD","LU2089984988.USD","LU2112291526.USD","LU0256863902.USD","LU1732799900.SGD","LU1267930490.SGD","IE0009355771.USD","LU0738911758.USD","LU1732800096.USD","LU1551013425.SGD","LU1037948897.HKD","LU0211327993.USD","LU0943347566.SGD","IE00BJJMRZ35.SGD","SG9999003800.SGD","LU0689472784.USD","LU0211328371.USD","LU0965509283.SGD","LU2237443465.HKD","LU2237443622.USD","LU1267930573.SGD","LU2087621335.USD","LU2237443382.USD","IE00B4R5TH58.HKD","SG9999015986.USD","BK4534","LU2237443549.SGD","BK4007"],"gpt_icon":0},{"id":"2486835896","title":"健康巡讲广泛使用的甲状腺药片可能与骨质流失有关","url":"https://stock-news.laohu8.com/highlight/detail?id=2486835896","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486835896?lang=zh_cn&edition=full","pubTime":"2024-11-27 03:58","pubTimestamp":1732651096,"startTime":"0","endTime":"0","summary":"健康巡讲广泛使用的甲状腺药片可能与骨质流失有关健康巡礼》每周二和周四出版。甲状腺药片与骨质流失有关 下周在芝加哥举行的北美放射学会年会上公布的一项研究 ，一种广泛使用的治疗甲状腺功能低下的药物可能与骨质流失有关。在一项对近450名老年人进行的研究中，在中位随访6.3年期间，这种药物与全身骨质和骨密度的更大损失有关。即使服用者的甲状腺激素水平处于正常范围，情况也是如此。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nL3T3MX1MV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1291159041.SGD","LU1983299246.USD","LU0198837287.USD","LU1267930573.SGD","LU0795875169.SGD","LU2237443978.SGD","LU0965509010.AUD","LU1057294990.SGD","LU1496350502.SGD","LU2087621335.USD","LU0545039389.USD","LU2347655156.SGD","SG9999001440.SGD","SG9999015952.SGD","ABBV","IE00BVYPNW00.USD","LU1267930490.SGD","LU0256863902.USD","IE00BVYPNV92.GBP","LU2089984988.USD","IE00BGHQF631.EUR","LU0820561818.USD","LU1244550577.SGD","IE00BJJMRZ35.SGD","LU2112291526.USD","BK4581","LU1093756325.SGD","LU1989772840.SGD","BK4139","LU1244550221.USD","LU0203345920.USD","LU0234572021.USD","LU0965509283.SGD","LU1496350171.SGD","LU0114720955.EUR","LU0203347892.USD","LU1244550494.USD","LU0211327993.USD","LU1037948897.HKD","LU1989771016.USD","LU1061106388.HKD","LU1093756168.USD","LU1732800096.USD","LU1003077747.HKD","LU0708994859.HKD","SG9999003800.SGD","IE0002141913.USD","LU2237443549.SGD","LU2468319806.SGD","LU2237443465.HKD"],"gpt_icon":0},{"id":"2486358998","title":"健康巡讲广泛使用的甲状腺药片可能与骨质流失有关","url":"https://stock-news.laohu8.com/highlight/detail?id=2486358998","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486358998?lang=zh_cn&edition=full","pubTime":"2024-11-27 03:58","pubTimestamp":1732651096,"startTime":"0","endTime":"0","summary":"健康巡讲广泛使用的甲状腺药片可能与骨质流失有关健康巡礼》每周二和周四出版。甲状腺药片与骨质流失有关 下周在芝加哥举行的北美放射学会年会上公布的一项研究 ，一种广泛使用的治疗甲状腺功能低下的药物可能与骨质流失有关。在一项对近450名老年人进行的研究中，在中位随访6.3年期间，这种药物与全身骨质和骨密度的更大损失有关。即使服用者的甲状腺激素水平处于正常范围，情况也是如此。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nL3S3MX1MV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1244550577.SGD","LU0965509010.AUD","LU1496350171.SGD","BK4581","LU0211327993.USD","LU0965509283.SGD","LU1244550494.USD","SG9999003800.SGD","LU2087621335.USD","LU2237443978.SGD","LU1003077747.HKD","LU0256863902.USD","LU1732800096.USD","LU0203347892.USD","LU0198837287.USD","LU1291159041.SGD","LU1267930573.SGD","LU0545039389.USD","BK4139","LU1061106388.HKD","LU1093756168.USD","LU1244550221.USD","LU1496350502.SGD","LU2347655156.SGD","LU0820561818.USD","SG9999015952.SGD","LU0114720955.EUR","LU2237443549.SGD","LU2468319806.SGD","LU1983299246.USD","LU1989772840.SGD","LU1057294990.SGD","LU0203345920.USD","LU2112291526.USD","LU2089984988.USD","IE00BJJMRZ35.SGD","LU1037948897.HKD","LU1267930490.SGD","IE00BVYPNV92.GBP","LU0795875169.SGD","LU0234572021.USD","SG9999001440.SGD","IE00BGHQF631.EUR","IE0002141913.USD","LU2237443465.HKD","LU1093756325.SGD","LU0708994859.HKD","IE00BVYPNW00.USD","LU1989771016.USD","ABBV"],"gpt_icon":0},{"id":"2486886505","title":"艾伯维上涨1.22%，报179.22美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2486886505","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486886505?lang=zh_cn&edition=full","pubTime":"2024-11-27 00:49","pubTimestamp":1732639758,"startTime":"0","endTime":"0","summary":"11月27日，艾伯维(ABBV)盘中上涨1.22%，截至00:49，报179.22美元/股，成交4.08亿美元。财务数据显示，截至2024年09月30日，艾伯维收入总额412.32亿美元，同比增长3.04%；归母净利润43.0亿美元，同比增长6.41%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/11/27004945722948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU1430594728.SGD","LU0965509010.AUD","LU0203347892.USD","LU1244550577.SGD","IE00BJJMRZ35.SGD","LU0256863902.USD","LU0158827948.USD","LU2347655156.SGD","LU2237443895.HKD","BK4533","LU0170899867.USD","LU0943347566.SGD","LU1989772923.USD","BK4585","LU1585245621.USD","SG9999011175.SGD","LU2133065610.SGD","LU1718418525.SGD","LU1496350502.SGD","SG9999001440.SGD","LU0949170772.SGD","LU0234570918.USD","LU2089984988.USD","IE00B42XCP33.USD","LU1037948541.HKD","LU0965509101.SGD","LU1496350171.SGD","LU2237443382.USD","LU2089284900.SGD","LU0820561818.USD","LU2089283258.USD","ABBV","LU2087621335.USD","LU0310800379.SGD","LU0861579265.USD","LU2237443622.USD","LU0912757837.SGD","LU1839511570.USD","LU1551013425.SGD","BK4139","LU0985320562.USD","IE00BFTCPJ56.SGD","LU1551013342.USD","SG9999015945.SGD","LU2468319806.SGD","IE00BGHQF631.EUR","LU1983299246.USD","LU2023251221.USD","LU0795875086.SGD","LU0553294199.USD"],"gpt_icon":0},{"id":"2486036674","title":"艾伯维上涨1.23%，报179.13美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2486036674","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486036674?lang=zh_cn&edition=full","pubTime":"2024-11-25 23:20","pubTimestamp":1732548017,"startTime":"0","endTime":"0","summary":"11月25日，艾伯维(ABBV)盘中上涨1.23%，截至23:20，报179.13美元/股，成交2.61亿美元。财务数据显示，截至2024年09月30日，艾伯维收入总额412.32亿美元，同比增长3.04%；归母净利润43.0亿美元，同比增长6.41%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/11/25232045666378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU0114720955.EUR","LU0708994859.HKD","LU0029864427.USD","BK4581","LU0661504455.SGD","LU0211328371.USD","LU1267930490.SGD","BK4550","IE00BVYPNV92.GBP","LU0689472784.USD","LU1989772840.SGD","SG9999001440.SGD","BK4533","LU2087621335.USD","LU0965509101.SGD","BK4559","IE00B3PB1722.GBP","IE00B42XCP33.USD","LU0912757837.SGD","LU1934455863.HKD","SG9999015952.SGD","IE00B2B36J28.USD","LU1291159041.SGD","LU1732799900.SGD","LU0170899867.USD","IE00BDGV0183.EUR","LU0795875169.SGD","LU0949170772.SGD","ABBV","LU2089984988.USD","LU0310800379.SGD","SG9999015945.SGD","LU0965509010.AUD","LU1496350502.SGD","BK4534","BK4566","LU0211327993.USD","LU0203347892.USD","LU0417517546.SGD","LU1244550221.USD","LU1551013342.USD","IE00BSNM7G36.USD","SG9999015978.USD","LU1244550494.USD","LU0738911758.USD","LU1057294990.SGD","LU0203345920.USD","LU1732800096.USD","LU2237443622.USD","LU0861579265.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbvie.com","stockEarnings":[{"period":"1week","weight":0.013},{"period":"1month","weight":0.0469},{"period":"3month","weight":-0.0923},{"period":"6month","weight":0.0307},{"period":"1year","weight":0.1509},{"period":"ytd","weight":0.1333}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"艾伯维公司注册成立于2012年4月10日，是一家全球性的、以研究为基础的生物制药公司。Abbvie公司从事开发和销售先进的疗法，来解决一些世界上最复杂和严重的疾病。Abbvie公司的产品主要集中在慢性自身免疫性疾病领域，包括类风湿性关节炎，牛皮癣和克罗恩病，银屑病和克罗恩病;低睾酮，HIV，子宫内膜异位症;甲状腺疾病;帕金森病;和并发症的慢性肾脏疾病和囊性纤维化相关的或其他健康问题。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.023334},{"month":2,"riseRate":0.833333,"avgChangeRate":0.030818},{"month":3,"riseRate":0.75,"avgChangeRate":0.006329},{"month":4,"riseRate":0.666667,"avgChangeRate":0.015725},{"month":5,"riseRate":0.666667,"avgChangeRate":0.006183},{"month":6,"riseRate":0.5,"avgChangeRate":0.00974},{"month":7,"riseRate":0.5,"avgChangeRate":0.01182},{"month":8,"riseRate":0.5,"avgChangeRate":-0.0014},{"month":9,"riseRate":0.5,"avgChangeRate":0.007813},{"month":10,"riseRate":0.666667,"avgChangeRate":0.012917},{"month":11,"riseRate":0.75,"avgChangeRate":0.065469},{"month":12,"riseRate":0.666667,"avgChangeRate":0.026607}],"exchange":"NYSE","name":"艾伯维公司","nameEN":"AbbVie"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾伯维公司,ABBV,艾伯维公司股票,艾伯维公司股票老虎,艾伯维公司股票老虎国际,艾伯维公司行情,艾伯维公司股票行情,艾伯维公司股价,艾伯维公司股市,艾伯维公司股票价格,艾伯维公司股票交易,艾伯维公司股票购买,艾伯维公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}